In Critical Path Update, Novartis Official Says Industry Should Pool Available Biomarker Data | GenomeWeb

A Novartis Pharmaceuticals official advocated sharing biomarker data among industry in a US Food and Drug Administration webcast discussing the agency’s “Critical Path” initiative.

Providing that pharma can protect its intellectual property, it would be advantageous for industry to pool biomarker data, Mathias Hukkelhoven, senior vice president and global head of drug regulatory affairs of Basel, Switzerland-based Novartis, said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.